The Life Science business of Merck broke ground at its Sheboygan, Wisconsin site, for the company’s first lateral flow membrane production facility in the United States. Lateral flow membranes are a key component in rapid diagnostic test kits for a variety of applications, including Covid-1 ... more
Merck has a good third quarter
Strong organic sales growth impacted by negative exchange rate effects
Merck generated very strong organic sales growth in the third quarter of 2018. However, this was impacted by negative exchange rate effects. Despite organic growth, EBITDA pre of the Group also declined in comparison with the year-earlier quarter owing to strong negative foreign exchange effects. Merck confirmed its forecast for the development of organic EBITDA pre for the full year 2018.
“2018 was a challenging year for Merck. We made future-oriented decisions that will lead to profitable growth as of 2019,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck. “In the third quarter, we generated strong organic sales growth across all three business sectors. In particular, Healthcare and Life Science performed well, delivering strong organic growth of nearly 10 percent.”
Group sales rose in the third quarter by 6.6% to € 3.7 billion (Q3 2017: € 3.5 billion). Organically, sales grew very strongly by 8.8%. The negative foreign exchange impact of –2.1% was primarily attributable to Latin American currencies such as the Argentinean peso and the Brazilian real.
EBITDA pre, the key financial indicator used to steer operating business, grew organically by 3.7%, thanks mainly to Healthcare and Life Science. However, significant negative foreign exchange effects of –9.5% caused EBITDA pre to decrease by –5.9% to € 963 million (Q3 2017: € 1,023 million). Group EBIT decreased by –43.1% to € 491 million (Q3 2017: € 862 million). Net income of the Merck Group fell in the third quarter by –47.2% to € 340 million (Q3 2017: € 644 million). The considerable declines in EBIT and Group net income are attributable to the gain of € 321 million on the divestment of the Biosimilars business reported in the previous year. Earnings per share pre declined by –7.7% to € 1.32 (Q3 2017: € 1.43)
- quarterly reports
- Merck
-
News
Merck Collaborates with Mammoth Biosciences to Scale New SARS-CoV-2 Test
Merck announced a collaboration with Mammoth Biosciences Inc., of South San Francisco, California, USA, for the development, scale-up and commercial production of Mammoth’s CRISPR-based SARS CoV-2 diagnostic test. Mammoth’s high-throughput systems will be compatible with both nasal swab and ... more
Merck acquires a French company
Merck enhanced its advanced bioprocess portfolio through the acquisition of RESOLUTION Spectra Systems, a Meylan, France-based leader in bioprocess analytical monitoring. The company offers Raman spectroscopy analysis through its GMP-ready instrumentation and software. Financial details of ... more
- Videos
- 1Fingerprint breakthrough in breast cancer detection
- 2New method for the detection of RNA viruses such as SARS-CoV-2
- 3New organ-on-chip pilot seeks to reduce animal testing in consumer health industry
- 4How nanoplastics can influence metabolism
- 5Self-driven laboratory speeds chemical discovery
- 6Capturing nanoplastics in tap water with light
- 7Next generation solar fuels: How a record-breaking copper catalyst converts CO₂ into liquid fuels
- 8Waters acquires Wyatt Technology for $1.36 billion
- 9A further advance in super-resolution fluorescence microscopy
- 10New analysis method developed for nano and quantum materials
- First comparative study on automated analysis methods of large data sets in microplastics research
- Beethoven’s genome: New study reveals hereditary diseases and a family mystery
- Future-oriented expansion of the LUM management
- Klara – A transparent fish for research on aging
- Electrocatalysis under the atomic force microscope